Suppl. Table 1. Baseline characteristics

|                                      |       |
|--------------------------------------|-------|
| Age (yr ± SD)                        | 39.5 (9.9) |
| Duration since MS diagnosis (yr ± SD)| 6.7 (5.9)  |
| Sex (f/m)                            | 65/48  |
| Previous DMT use before fingolimod start (no. (%)) | 91 (80.5) |
| Interferon beta                      | 45 (39.8) |
| Glatirameracetat                     | 27 (23.9) |
| Natalizumab                          | 14 (12.4) |
| Others                               | 5 (4.4)  |
| None previous DMT use (no. (%))      | 22 (19.5) |
| BMI (± SD)                            | 25.0 (4.7) |
| EDSS (± SD)                           | 2.8 (1.4)  |

Baseline characteristics of evaluated patients are depicted. DMT, disease modifying treatment. Other previous treatments included: Azathioprin (2), Laquinimod (3). During a standardized treatment switch procedure, injectables were stopped 2 weeks before fingolimod start, natalizumab was stopped 12 weeks before fingolimod start and other DMTs at least 6 months before fingolimod start. Yr, year; SD, standard deviation; f, female; m, male; no, number.